IO Biotech Inc. - IOBT Company Short-Term Debt

IO Biotech (IOBT) - corporate logo

IO Biotech, Inc. (IOBT) focuses on assisting patients with terminal melanoma and severe tumors. The financial model relies on the creation of personalized vaccines, the costs of which are fully reimbursed by insurance companies. The current metric stands at 0.00. The firm is currently completing the final stage of testing for its innovative drug as it approaches full-scale sales. This price chart below illustrates the asset's price action amid preparations for commercialization.

IOBT: iobiotech.com Short-Term Debt 07/04/2022 - 04/18/2026

IOBT (IO Biotech Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart IO Biotech|IOBT - Average Forecast Price
- market capitalization data:
Market Value IO Biotech, Inc.|IOBT - Total Company Value
- book capitalization data:
Net Assets per Single Share IO Biotech|IOBT - Total Stockholders' Equity|Market Capitalization to Book Value Ratio iobiotech.com|IOBT - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Equity Ratio IO Biotech, Inc.|IOBT - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio IO Biotech, Inc.|IOBT - Aggregate Debt Obligations|Debts to Book Capitalization IO Biotech, Inc.|IOBT - Long-Term Debt Volume|Company Short-Term Debt IO Biotech
Analysis of all company metrics:IO Biotech IOBT
Finished products of iobiotech.com

For IO Biotech, Inc. (IOBT), which develops advanced cancer vaccines, short-term debt reflects loan obligations maturing within one year. This metric aggregates all current borrowings to determine the immediate pressure on liquidity. By analyzing the short-term debt trajectory, an investor assesses the company's ability to service its obligations without disrupting R&D. A decrease in this indicator confirms financial autonomy, ensuring the sustainability of the strategy to achieve leadership in combination therapy.

Competitor analysis for IO Biotech, Inc.

IBRX (ImmunityBio) - Company Short-Term Debt|IMCR: Short-Term Debt|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt ZYME (Zymeworks Inc.)|Short-Term Debt tangotx.com|IOVA: Company Short-Term Debts|Short-Term Indebtedness Immatics NV IMTX|XNCR: Company Current Liabilities|CMPX - Short-Term Debt|Company Current Liabilities Replimune Group, Inc. (REPL)|LYEL - Company Short-Term Loans and Borrowings|Innate Pharma - Company Short-Term Debts|PYXS (Pyxis Oncology) - Short-Term Debt Volume|Company Short-Term Debt CGEN|Company Current Liabilities STRO|Company Short-Term Debt INKT (MiNK Therapeutics, Inc.)|Company Current Liabilities werewolftx.com HOWL|Company Current Liabilities IMMX (Immix Biopharma)|alxoncology.com - Company Short-Term Debts|Cue Biopharma (CUE) - Company Short-Term Debt|PDSB: Company Short-Term Indebtedness|Company Short-Term Debt SONN|Short-Term Debt MAIABiotech.com|Liminatus Pharma LLC - Company Current Liabilities|Short-Term Indebtedness Lava Tx (LVTX)|Company Current Liabilities NextCure Corp|Amount of Current Liabilities leaptx.com (LPTX)|Company Short-Term Debts Intensity Therapeutics, Inc.|Company Short-Term Loans and Borrowings Sensei Biotherapeutics Inc SNSE|TOVX (Theriva Biologics) - Company Short-Term Debts|GRTS: Short-Term Debt|Company Short-Term Debt Kineta Bio KA|NexImmune Corporation (NEXI) - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts VCNX|HARP - Company Short-Term Debt